Figura et al. have compared the activity of intrathecal trastuzumab (18 patients), intrathecal MTX or thioTEPA (15 patients), or WBRT alone (23 patients) in LM from HER-2 positive BC. The gene discussed is ERBB2; the disease is breast cancer.